Caladrius Biosciences

373 articles with Caladrius Biosciences

• Caladrius Biosciences to Present at the Life Sciences Investor Forum on September 17th

  9/14/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that management will present a company overview at the Virtual Life Sciences Investor Forum, which is being held on Thursday, September 17, 2020.

• Caladrius Biosciences to Participate in Landmark’s 10th Annual Investing for Cures Virtual Forum

  9/10/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in Landmark’s 10th Annual Investing for Cures Virtual Forum being held September 16-17, 2020.   

• Caladrius Biosciences Announces Registration of HONEDRA® Trademark and New Patent in Japan

  9/9/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has received trademark registration from the Japan Patent Office (“JPO”) for the Company’s use of HONEDRA® as the brand name for CLBS12,

• Caladrius Biosciences to Present at H.C. Wainwright 22nd Annual Global Investment Virtual Conference

  9/8/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the H.C. Wainwright 22 nd Annual Global Investment Conference, held virtually this year, September 14-16, 2020. Presentation Details: Date & Time: Tuesday, Septembe

• Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020

  9/3/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020. Title: Repair of the microcirculation reverses ischemic tissue damage Presenter: Dougl

• Caladrius Biosciences to Present at the LD 500 Virtual Conference on September 1, 2020 at 11:40 AM Eastern Time

  8/27/2020

  Caladrius Biosciences, Inc. today announced that management has been invited to present at the LD 500 virtual investor conference being held September 1-4, 2020.

• Caladrius Biosciences Provides Corporate Update and Reports 2020 Second Quarter Financial Results

  8/13/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, provides a corporate update and reports financial results for the three and six months ended June 30, 2020.

• Caladrius Biosciences to Host Second Quarter 2020 Financial Results Conference Call on Thursday, August 13, 2020

  8/6/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced that it will report financial results for the three and six months ended June 30, 2020 after the close of the U.S. financial markets on Thursday, August 13, 2020. Caladrius management will host a conference c

• 

  BioSpace Movers & Shakers, July 31

  7/31/2020

  Biopharma and life science companies strengthen their leadership teams and board with these Movers & Shakers.

• Caladrius Biosciences Appoints Dr. Michael H. Davidson to Board of Directors

  7/28/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not simply manage, disease, today announced the appointment of Michael H. Davidson, MD to its Board of Directors. Dr. Davidson, an industry leader and expert in preventative cardiology and lipidology, is the Founder and Chief Scientific Officer of Corvi

• Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase

  6/2/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. David J. Mazzo, Ph.D., President and Chief Executive Officer of Caladrius Biosciences, will pre

• Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  5/28/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,084,850 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.0625 per share

• Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

  5/6/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced it will present full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions (“SCAI”) 2020 Scientific Sessions Virtu

• Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020

  4/30/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it will report financial results for the three months ended March 31, 2020 after the close of the U.S. financial markets on Thursday, May 7, 2020. Caladrius management will host a conference call for investor

• Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  4/27/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,162,166 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.3125 per share, in a registere

• Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

  4/23/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,162,166 shares of its common stock, at a purchase price of $2.3125

• Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

  3/5/2020

  Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, announces financial results for the three and twelve months ended December 31, 2019.

• 

  BioSpace Movers and Shakers Nov. 5

  11/5/2018

  Biopharma companies make key appointments to fill leadership positions. Let's take a look!

• Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina

  6/19/2018

  Caladrius Biosciences, Inc. announces today that that the U.S. Food and Drug Administration has granted RMAT designation to the Company’s late-stage CD34+ cell therapy program.

• Caladrius Biosciences Announces Completion of Enrollment of Phase II T-Rex Clinical Trial of CLBS03 for Type 1 Diabetes

  1/18/2018

  Primary endpoint topline data to be reported in early 2019.